Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ: APLS )

24.37 -0.81 (-3.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. 
Via Benzinga
Why Are Apellis Pharmaceuticals Shares Trading Higher Today?
Via Benzinga
Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval
Apellis is soon to launch its newest drug, Syfovre, for geographic atrophy patients. 
Via Investor's Business Daily
Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Owlet Shares Are Trading Higher By Over 45%; Here Are 20 Stocks Moving Premarket
Gainers Troika Media Group Inc (NASDAQ: TRKA) shares rose 65.9% to $0.37 in pre-market trading after dropping 4% on Friday. 
Via Benzinga
What 5 Analyst Ratings Have To Say About Apellis Pharmaceuticals
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start another day of trading with a breakdown of the biggest pre-market stock movers traders need to know about for Tuesday! 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
Via Benzinga
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Why InMed Pharmaceuticals Shares Tumbled 28%; Here Are 67 Biggest Movers From Friday
Gainers AGBA Group Holding Limited (NASDAQ: AGBA) gained 50.7% to close at $6.78 on Friday. 
Via Benzinga
Foot Locker, Ross Stores, Palo Alto Networks, And Other Big Gainers From Friday
U.S. stocks closed higher on Friday, with the Dow Jones gaining around 200 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Why PaxMedica Shares Are Trading Higher By Over 53%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Gainers PaxMedica, Inc. (NASDAQ: PXMD) gained 53.5% to $2.38 after the company announced an equity investment agreement for up to $20 million with Lincoln Park Capital. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Apellis Pharma Shares Jump As FDA Accepts Its Lead Product Application For Eye Disease
Via Benzinga
Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment
The delay is at Apellis' behest. The company wanted to include updated data in its request. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.